Top Biotech Stocks to Watch: 12 Strong Momentum Picks, Entry Zones and Risk Signals

Top Biotech Stocks to Watch: 12 Strong Momentum Picks, Entry Zones and Risk Signals

Several biotech stocks are showing strong technical momentum, but only a handful currently combine bullish trend strength, positive volume confirmation and manageable entry risk. Based on the latest screener snapshot, stocks such as TXG, MYGN, IMVT, PSIL, MDGL, KYMR and ADPT stand out for their strong scores, bullish directional indicators and improving medium-term returns.

However, investors should avoid chasing stocks that are already extended or overbought. Names including MRVI, ACHC, ATAI and CDNA have generated strong gains, but their elevated RSI readings suggest that profit-booking or consolidation may follow.

This analysis is based exclusively on technical indicators, momentum signals, trend strength, volume behaviour, entry zones, support levels and risk-reward data included in the supplied stock screener.

Best Biotech Stocks to Watch at a Glance

Top Biotech Stock Picks Based on Momentum and Trend Strength

1. TXG

TXG is one of the strongest technically positioned stocks in the screener. It carries a score of 12, a Strong Buy signal and a 77% confidence reading.

• Current price: $43.74
• RSI: 66.7
• ADX: 46.7
• One-month return: 37.76%
• Three-month return: 73.30%
• Target 1: $48.99
• Target 2: $51.61
• Target 3: $65.03
• Stop loss: $39.81

The stock is trading above both its 50-day and 200-day moving averages, while bullish directional movement remains dominant. However, the current price is already above the suggested entry zone of $30.79 to $39.14. Fresh buyers may therefore prefer a controlled pullback rather than chasing the price.

2. MYGN

MYGN has a strong combination of bullish trend confirmation, rising volume and improving medium-term returns. The stock has gained 45.41% over one month and 23.60% over three months.

• Current price: $6.18
• Score: 12
• Confidence: 77%
• RSI: 66.6
• Target 1: $6.82
• Target 2: $7.14
• Target 3: $8.18
• Stop loss: $5.70

The stock is above its preferred entry zone of $4.60 to $5.70. Existing holders may consider protecting gains, while new buyers may wait for a pullback toward support.

3. IMVT

IMVT is showing a healthy breakout structure supported by a Strong Buy signal and rising OBV trend. Its RSI of 63.5 suggests positive momentum without entering extreme overbought territory.

• Current price: $40.26
• Score: 12
• One-month return: 19.79%
• Three-month return: 47.20%
• Target 1: $43.44
• Target 2: $45.03
• Target 3: $56.45
• Stop loss: $37.87

The screener’s preferred entry zone is $36.39 to $38.84. Since the stock is already trading above that range, a minor pullback may offer a better risk-controlled setup.

4. PSIL

PSIL has a score of 12 and a Strong Buy rating, supported by bullish MACD, rising volume, positive directional strength and strong medium-term returns.

• Current price: $24.13
• RSI: 61.7
• One-month return: 23.24%
• Three-month return: 29.66%
• Target 1: $26.20
• Target 2: $27.24
• Target 3: $29.72
• Stop loss: $22.57

The stock has moved above its suggested entry zone of $20.78 to $23.09. Momentum remains positive, but new positions may carry better risk control closer to support.

5. MDGL

MDGL is one of the more stable high-priced biotechnology names in the list. It has a score of 12, bullish MACD, rising OBV and a golden moving-average structure.

• Current price: $553.48
• RSI: 60.0
• Target 1: $597.27
• Target 2: $619.17
• Target 3: $602.83
• Stop loss: $520.64
• Support 1: $530.07

The stock is trading above the suggested entry range of $495.69 to $531.45. Its trend remains constructive, although the screener confidence is lower at 47%, suggesting that position sizing should remain disciplined.

Stocks Showing Strong Momentum but Elevated Risk

The following stocks have high technical scores but are already overbought or extended. They may remain strong, but chasing them at current levels could expose traders to sudden pullbacks.

Why CDNA, MRVI, ATAI and ACHC Need Caution

These stocks lead the screener with scores of 13, but their RSI values range from 73.1 to 82.2. RSI readings above 70 generally indicate that momentum is strong but the stock may be vulnerable to consolidation or profit-booking.

CDNA is particularly extended, with a 70.88% one-month gain and a 77.21% three-month return. MRVI has gained 112.32% over three months, while ATAI has risen 74.40% in one month. Such moves can continue, but the risk of buying near a short-term peak is materially higher.

Best Pullback Candidates

Some technically strong stocks are trading above their preferred entry zones. These may become more attractive if they retrace toward support without breaking their bullish structure.

Early-Stage Biotech Stocks Worth Monitoring

Not every Strong Buy signal is immediately actionable. Several stocks show improving momentum but have met only two or three of the screener’s six entry conditions.

BLUE

BLUE has a Strong Buy rating and is trading near its suggested entry range of $18.15 to $18.48. However, only two of six entry conditions have been met, while MACD and directional indicators remain bearish. It may be better treated as a watchlist candidate rather than an immediate entry.

FATE

FATE has gained 46.32% over one month and 102.92% over three months. Its broader momentum is strong, but only two entry conditions are currently satisfied. A pullback toward the $1.80 to $2.66 zone may offer better risk control.

VCYT

VCYT has a Strong Buy rating, a score of 9 and a positive three-month return of 79.02%. However, its MACD remains bearish and only two of six entry conditions have been met. The stock may need renewed momentum confirmation before becoming actionable.

TGTX

TGTX remains in a broader uptrend, with a 59.97% three-month return. Still, only two entry conditions are satisfied and OBV is not confirming strongly. The stock may require a breakout above resistance before offering a higher-confidence setup.

Stocks With Strong Entry Signals but Weak Risk-Reward

Some stocks meet four or five technical entry conditions but still carry an unattractive risk-reward ratio of about 1.3:1 or lower.

• BCAB: Five of six conditions met, but the screener flags poor risk-reward.
• TNYA: Strong Entry signal, but the current price is already above the preferred entry zone.
• ANNX: Strong trend continuation setup, though the reward relative to risk remains limited.
• CGEN: Five entry conditions met, but the current price is above its preferred range.
• FHTX: Four conditions met, although the current price is above the suggested entry zone.
• INSM: Four conditions met, but trend and moving-average signals remain mixed.

A technically strong setup does not automatically make a stock attractive. Entry price, stop placement and potential upside must all be considered together.

Biotech Stocks to Avoid Based on the Screener

The weakest stocks in the dataset combine negative scores, bearish momentum, falling volume trends and confirmed downtrends. These names may remain risky until they show a clear reversal.

Why These Stocks Are Considered High Risk

Most of the weakest stocks are trading below their 50-day and 200-day moving averages. They also show bearish MACD signals, falling OBV trends, negative ROC readings and weak directional movement.

An oversold RSI or stochastic reading alone does not confirm a reversal. In a strong downtrend, oversold stocks can continue falling for an extended period.

Key Technical Signals Investors Should Understand

RSI

The Relative Strength Index measures momentum. Readings above 70 generally indicate overbought conditions, while readings below 30 indicate oversold conditions. Neither reading should be used as a standalone buy or sell signal.

MACD

A bullish MACD reading suggests improving momentum, while a bearish MACD signal indicates weakening momentum. Stocks with a Strong Buy score but bearish MACD may require additional confirmation.

ADX and Directional Indicators

ADX measures trend strength. An ADX above approximately 25 usually indicates a meaningful trend. The direction of that trend is determined by comparing +DI and -DI.

• If +DI is above -DI, the directional trend is generally bullish.
• If -DI is above +DI, the directional trend is generally bearish.
• A high ADX with bearish directional movement can confirm a strong downtrend.

OBV Trend

On-Balance Volume helps assess whether volume supports the price move. Rising OBV can strengthen a bullish setup, while falling OBV may signal weak participation or distribution.

Golden and Death Cross

A golden cross occurs when the shorter moving average rises above the longer moving average. A death cross occurs when the shorter moving average falls below the longer moving average. These signals are more useful when combined with trend strength and volume confirmation.

Which Biotech Stocks Look Strongest Right Now?

TXG, MYGN, IMVT, PSIL, MDGL, KYMR and ADPT appear to be among the strongest technically positioned stocks in the screener. They combine high scores, bullish directional movement, positive medium-term returns or volume confirmation.

However, several of these stocks are trading above their preferred entry zones. Investors may therefore consider waiting for a pullback, consolidation or fresh breakout confirmation instead of entering after an extended move.

Which Biotech Stocks Are Overbought?

CDNA, MRVI, ATAI, ACHC, CPRX and SEER are overbought or close to overbought territory. Their momentum remains strong, but the risk of profit-booking is elevated.

Existing holders may consider tightening stop-loss levels. New buyers should avoid assuming that a high technical score automatically guarantees further immediate gains.

Which Stocks Should Be Avoided?

KALA, IONS, PHGE, NTLA, OGEN, RXRX, BEAM and DNA are among the weakest setups in the screener. They show negative scores, bearish momentum, falling volume trends and weak or confirmed downtrends.

These stocks may only become more attractive after forming a stable base, reclaiming major moving averages and generating bullish momentum confirmation.

Important Data Quality Note

Several tickers in the supplied dataset contained #REF! spreadsheet errors. These included SGMO, RPTX, CLVS, NVTA, OLINK, MNMD, CYBN, FTRP, ETNB, VTYX, DAWN, VERV, FOLD, APLS and DYNE, among others.

These rows were excluded because their price, indicator, score, entry and risk data could not be evaluated reliably. The duplicate NKTX row was also treated as a single stock observation.

The screener currently favours biotech stocks with sustained momentum, rising volume and bullish directional movement. TXG, MYGN, IMVT, PSIL, MDGL, KYMR and ADPT appear stronger than most peers, but several are already above their ideal entry ranges.

Stocks such as CDNA, MRVI, ATAI and ACHC remain powerful momentum names, although their overbought readings make fresh entries riskier. Meanwhile, deeply oversold stocks such as KALA, IONS and PHGE should not be treated as automatic bargain opportunities because their downtrends remain technically confirmed.

Investors should combine technical screening with company fundamentals, clinical trial developments, regulatory updates, cash runway, dilution risk and broader market conditions before making any decision.

Disclaimer: This article is based on technical screener data supplied for analysis and is intended only for informational and educational purposes. It is not investment advice or a recommendation to buy or sell any security. Biotechnology stocks can be highly volatile and may be affected by clinical trial results, regulatory decisions, financing needs and dilution. Investors should conduct independent research and consult a qualified financial adviser before making investment decisions.